Samir Nusair MD 🇮🇱

Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial Fc receptor blockade by nipocalimab 15 mg/kg significantly improved clinical disease activity versus placebo and was safe and well tolerated in participants with moderate-to-severe, active Sjögren's d...

Sjogren disease therapy making nice progress since I reviewed pilocarpine for xerostomia in SS 25 years ago. Read "research in context" box.
www.thelancet.com/journals/lan...

Very interesting 👇

small vessel vasculitis-necrosis?

Antifibrotic therapy does not alter the natural history of #pulmonaryhypertension in #pulmonaryfibrosis and other #progressivePF #fibroticILD

bmcpulmmed.biomedcentral.com/articles/10....

The prognostic importance of worsening dyspnoea in systemic sclerosis related interstitial lung disease To determine the prognostic importance of worsening dyspnoea in systemic sclerosis (SSc) related interstitial lung disease (ILD).SSc patients were rec…

Dyspnea worsening is a strong predictor of ILD progression in #Scleroserma and unlinked to changes in pulmonary function test
www.sciencedirect.com/science/arti...

Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis - Japanese Journal of Radiology Purpose Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose...

FDG accumulation (or lack of uptake) within interstitial lesions does not predict acute exacerbation risk in lung cancer
#pulmonaryfibrosis
link.springer.com/article/10.1...

Inhaled Recombinant human GM-CSF given 48w shows clinically significant ,around 10% rise in DLCO, with some yet not statistically significant improvement in QOL or Exercise capacity in #alveolarproteinosis #raredisease

Our dog is inspired in her sleep, dreaming and runnig while I listen to an old lecture from the late Prof. Brian Whipp
#ExercisePhysiology #ExerciseTesting
#ERSCongress 2007

Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials.

Another therapeutic option for #pulmonaryfibrosis is coming up: Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist for IPF and PPF
journal.chestnet.org/article/S001...

All is good. Would reclassification help us to adjust optimal treatment and improve outcomes and clinical decisions? I sure hope so.
publications.ersnet.org/content/erj/...

Calcium Supplementation, Genetic Susceptibility, and Idiopathic Pulmonary Fibrosis Risk: A Prospective Study The association between calcium supplementation and the risk of incident idiopathic pulmonary fibrosis (IPF) is largely unknown.This study aimed to in…

Intriguing findings suggest that #Calcium Supplementation and even more together with Genetic Susceptibility may increase the incidence of Idiopathic #PulmonaryFibrosis.
A prospective cohort study.
www.sciencedirect.com/science/arti...

Seems my point is well taken. Injury, enforces abstaining from exercise or modifications that compromise benefit on mitochondria.

I presume there is a J-curve in which heavy repeated load may have eventually a toll on the integrity and function of joints and supporting soft tissue.

How come with increased wisdom and knowledge in this age there is more idiocy?

A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss - Nature Metabolism In this study, the authors describe SANA, a nitroalkene derivative of salicylate, as a potential activator of creatine-dependent energy expenditure and thermogenesis in adipose tissue. Preclinical and...

A new approach to achieve weight loss, by increasing thermogenesis and promoting metabolism
www.nature.com/articles/s42...

the effect on 'later life' is valid if you maintain a life long training pattern

On the Cover of @annalsats.bsky.social a picture of the pediatric department from which the senior author of this paper comes. The building was savagely attacked by an Iranian missile On June the 19th.

Dupilumab and #lymphoma risk among patients with #asthma: a population-based cohort study #BiologicsAsthma
Increased incidence of T and NK cell lymphoma and CTCL.
Clinical implications, yet to be determined.
publications.ersnet.org/content/erj/...

פגיעת הטיל האיראני במכון ויצמן: "יש מעבדות שאיבדו הכול" הטיל האיראני שפגע השבוע במכון ויצמן למדע שברחובות גרם נזק כבד והותיר לא מעט לבבות שבורים של מיטב המוחות המדעיים בישראל. מתוך השבר הנורא נולדה מחויבות לשיקום המחקר. פרופ' אלדד צחור, חוקר מחלות לב: "המע...

On the devastating damage the researchers at Weizmann institute sustained from an Iranian missle

www.ynet.co.il/health/artic...

Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease <p>Dr. Mohleen Kang chats with Dr. Kerri Johannson and Dr. Tamera Corte about their article, "<a rel="nofollow"href="https://www.ats...

An @atscommunity.bsky.social podcast on environmental factors contributing to interstitial lung disease #pulmonaryfibrosis #fibroticILD
castbox.fm/app/castbox/...

Rentosertib, A generative AI-discovered TNIK inhibitor for idiopathic #pulmonaryfibrosis: a randomized phase 2a trial
Interesting if consistently confirmed effective, seems to have a relatively small rate of GI side effects.
www.nature.com/articles/s41...

So banal and so understanable.

Remarkable: a treatment for progressive pulm. fibrosis #fibroticILD. #Nerandomilast a molecule with #antifibrotic and anti-inflammatory effect, slows down FVC deterioration. Additionally, a weak signal of benefit on secondary end points, seen beyond week 52 of therapy.
www.nejm.org/doi/full/10....

Nerandomilast slows FVC deterioration in IPF patients without/with background #antifibrotic therapy.
- No additional protection from IPF exacerbation
- Pirfenidone decreases plasma levels of Nerandomilast by 50% as opposed to nintedanib.
#pulmonaryfibrosis #ATS2025
www.nejm.org/doi/full/10....

First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate | NEJM Prednisone is currently recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side effects. Methotrexate, which is recommended as a second-line treatment, ap...

Methotrexate vs. PDN as 1st line therapy for pulmonary #sarcoidosis
At 24 weeks MTX was non-inferior to PDN in the effect on FVC, however as may be expected the effect of PDN was achieved earlier than MTX. Important, as MTX could be a good alternative to PDN. #ATS2025
www.nejm.org/doi/full/10....

Should read this study carefully!
#Nerandomilast from @boehringerglobal.bsky.social an orally administered preferential inhibitor of phosphodiesterase 4B in #pulmonaryfibrosis. Results of a phase 3 study with background #antifibrotic therapy. #ATS2025
www.nejm.org/doi/full/10....

YouTube video by MusicManic George helps Ringo write ‘Octopus’ Garden’ Get Back #thebeatles #beatles #getback #music

Octopus garden
Lovely 😍
youtube.com/shorts/PpwlY...

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomize...

Semaglutide can reverse #fibrosis in the liver. Can it reverse fibrosis in other organs?
www.nejm.org/doi/full/10....

Informative review-editorial on #bronchiectasis

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis | NEJM In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...

Phase 3 Trial of the DPP-1 Inhibitor #Brensocatib in #Bronchiectasis
Interesting that this study performed during the height of the COVID19 pandemic with probably reduced incidence of exacerbations in the placebo group, still shows a stat. significant signal of benefit.
www.nejm.org/doi/full/10....